Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


Interstitial granulomatous dermatitis successfully treated with etanercept

Unknown ethiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy

Zavier Shawkat Ahmed, Sabaa Joad, Manpreet Singh, Sabiha S. Bandagi

USA Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, Jamaica, NY, USA

Am J Case Rep 2014; 15:94-96

DOI: 10.12659/AJCR.890074

Available online: 2014-03-01

Published: 2014-03-01


Background: Interstitial granulomatous disease (IGD) is a rare skin condition that presents with erythematous and violaceous plaques, and may be associated with pruritus and pain. The cause remains unknown, but is often associated with autoimmune disease and drug-related adverse effects. It is diagnosed via biopsy, and the treatment remains unclear.
Case Report: We report a case of biopsy-proven IGD associated with rheumatoid arthritis that was treated successfully with etanercept therapy.
Conclusions: We emphasize that anti-TNF antibodies may be clinically effective for the treatment of IGD.

Keywords: etanercept, rheumatoid arthritis, Interstitial Granulomatous Dermatitis (IGD)